StockData
NeuroSense Therapeutics Ltd. logo

NeuroSense Therapeutics Ltd. (NRSN) stock

NRSNNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as NRSNW
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 31, 2026Score 4/30
$1.37−0.14 (-9.27%)

Close on Nov 18, 2026Market cap $2.52MP/E –Yield –

NeuroSense Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

For fiscal 2025 it was -$7.67M. The highest annual figure on record is -$582.00K in fiscal 2019.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$7.67M–
FY2024Dec 31, 2024-$10.14M–
FY2023Dec 31, 2023-$8.35M–
FY2022Dec 31, 2022-$7.62M–
FY2021Dec 31, 2021-$1.54M–
FY2020Dec 31, 2020-$695.00K–
FY2019Dec 31, 2019-$582.00K–

More NeuroSense Therapeutics figures

See a number that looks wrong?